Who are metoprolol, amiodarone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lidocaine + Esmolol (Combo), Nicardipine , Esmolol, Atenolol Pill, Nebivolol Pill, Prophylactic esmolol, Bisoprolol+pyridostgmine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metoprolol-amiodarone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

metoprolol, amiodarone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

metoprolol, amiodarone (metoprolol, amiodarone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-1 selective adrenergic antagonist; Class III antiarrhythmic. Area: Cardiovascular.

marketed Beta-1 selective adrenergic antagonist; Class III antiarrhythmic Beta-1 adrenergic receptor; Potassium channels (hERG and others) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

metoprolol, amiodarone (metoprolol, amiodarone) — Kuopio University Hospital. Metoprolol is a beta-1 selective adrenergic antagonist that reduces heart rate and blood pressure, while amiodarone is a class III antiarrhythmic that blocks potassium channels and prolongs the action potential duration to prevent arrhythmias.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
metoprolol, amiodarone TARGET	metoprolol, amiodarone	Kuopio University Hospital	marketed	Beta-1 selective adrenergic antagonist; Class III antiarrhythmic	Beta-1 adrenergic receptor; Potassium channels (hERG and others)
Lidocaine + Esmolol (Combo)	Lidocaine + Esmolol (Combo)	Cedars-Sinai Medical Center	marketed	Local anesthetic + Beta-1 selective adrenergic antagonist	Voltage-gated sodium channels (lidocaine); Beta-1 adrenergic receptor (esmolol)
Nicardipine , Esmolol	Nicardipine , Esmolol	Nanjing Medical University	marketed	Calcium channel blocker + Beta-1 selective adrenergic antagonist combination	L-type calcium channels; Beta-1 adrenergic receptor
Atenolol Pill	Atenolol Pill	Tartu University Hospital	marketed	Beta-1 selective adrenergic antagonist (beta-blocker)	Beta-1 adrenergic receptor
Nebivolol Pill	Nebivolol Pill	Tartu University Hospital	marketed	Beta-1 selective adrenergic antagonist (beta-blocker)	Beta-1 adrenergic receptor
Prophylactic esmolol	Prophylactic esmolol	Hospital de Base	marketed	Beta-1 selective adrenergic antagonist (beta blocker)	Beta-1 adrenergic receptor
Bisoprolol+pyridostgmine	Bisoprolol+pyridostgmine	Seoul National University Hospital	marketed	Beta-1 selective adrenergic antagonist + Cholinesterase inhibitor combination	Beta-1 adrenergic receptor; Acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-1 selective adrenergic antagonist; Class III antiarrhythmic class)

Kuopio University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metoprolol, amiodarone — Competitive Intelligence Brief. https://druglandscape.com/ci/metoprolol-amiodarone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab